INTRINSIC: A Multi-Arm Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer
Condition: Colorectal Cancer
Sponsor: Hoffmann-La Roche
Full Title
Protocol WO42758: A Phase I/Ib Global, Multicenter, Open-label Umbrella Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer
Study Treatment
Oral KRAS G12C inhibitor Divarasib in combination with standard of care chemotherapy regimen FOLFOX or FOLFIRI
Eligibility/Info
Stage IV colon or rectal adenocarcinoma
KRAS G12C mutation and the absence of another oncogenic mutation
No prior systemic therapy in the advanced/metastatic setting
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
